Hana Initiates Marqibo Phase II Trial in Relapsed/Refractory ALL
Hana Biosciences has initiated a multicenter phase II clinical trial of Marqibo (vincristine sulfate liposome injection) in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The study is designed to support a phase III pivotal clinical trial of Marqibo for ALL, the company said in a press release. The primary objective of the phase II open-label study is to assess the efficacy of weekly doses of Marqibo plus pulse dexamethasone as measured by complete response rate. Hana expects to enroll up to 44 patients.
SOUTH SAN FRANCISCO, CaliforniaHana Biosciences has initiated a multicenter phase II clinical trial of Marqibo (vincristine sulfate liposome injection) in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The study is designed to support a phase III pivotal clinical trial of Marqibo for ALL, the company said in a press release. The primary objective of the phase II open-label study is to assess the efficacy of weekly doses of Marqibo plus pulse dexamethasone as measured by complete response rate. Hana expects to enroll up to 44 patients.
